<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34978">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01691820</url>
  </required_header>
  <id_info>
    <org_study_id>115639</org_study_id>
    <nct_id>NCT01691820</nct_id>
  </id_info>
  <brief_title>Study to Explore CMV Infection in Adolescent Girls</brief_title>
  <official_title>A Study in Adolescent Females to Explore Cytomegalovirus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Finland: Ministry of Social Affairs and Health</authority>
    <authority>Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS)</authority>
    <authority>Brazil: Agência Nacional de Vigilância Sanitária (ANVISA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to estimate the incidence of CMV secondary infections (re-infections/
      re-activation) and the incidence of CMV primary infections in adolescent females.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>Occurrence of CMV secondary infections determined in all seropositive subjects in terms of antibody concentrations and viral load.</measure>
    <time_frame>Every 4 months from Month 0 to Month 36</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of CMV primary infections determined in all seronegative subjects in terms of antibody concentrations.</measure>
    <time_frame>Every 4 months from Month 0 to Month 36</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Infections, Cytomegalovirus</condition>
  <arm_group>
    <arm_group_label>Group S+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CMV seropositive subjects at inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group S-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CMV seronegative subjects at inclusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.</description>
    <arm_group_label>Group S-</arm_group_label>
    <arm_group_label>Group S+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urine collection</intervention_name>
    <description>Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.</description>
    <arm_group_label>Group S-</arm_group_label>
    <arm_group_label>Group S+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dry urine collection</intervention_name>
    <description>Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.</description>
    <arm_group_label>Group S-</arm_group_label>
    <arm_group_label>Group S+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Saliva collection</intervention_name>
    <description>Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.</description>
    <arm_group_label>Group S-</arm_group_label>
    <arm_group_label>Group S+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urine and/ or saliva collection from newborn in case of pregnancy</intervention_name>
    <description>Samples collected upon delivery or within 10 days of delivery.</description>
    <arm_group_label>Group S-</arm_group_label>
    <arm_group_label>Group S+</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A female adolescent between, and including 10 and 17 years at the time of enrolment
             regardless of pregnancy status and contraception method used or not used.

          -  Subjects who the investigator believes that the subject and/or the subject's
             parent(s)/Legally Acceptable Representative(s) (LAR[s]) can and will comply with the
             requirements of the protocol.

          -  Written informed assent and/or consent obtained from the subject and/or the
             parent(s)/LAR(s) of the subject.

          -  Subject is likely to remain in the area and/or return for required study Site Visits
             and complete Sample Collection Visits.

        Exclusion Criteria:

          -  Child in care.

          -  Use or planned use of any investigational or non-registered antiviral drug or vaccine
             during the study period.

          -  Known medical history of any recurrent clinical herpes episodes requiring episodic or
             chronic suppressive treatment with oral or parenteral antiviral treatment such as
             acyclovir, famciclovir, valacyclovir or any other anti-herpes virus anti-viral during
             the year preceding enrolment. Topical anti-viral are allowed.

          -  Subjects with history of previous vaccination against CMV.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within 6
             months prior to Visit 1 or planned administration during the study. Inhaled and
             topical steroids are allowed.

          -  Administration of immunoglobulins and/or any blood products within 3 months prior to
             Visit 1 or planned administration during the study.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including
             HIV-infection, based on medical history and physical examination (no laboratory
             testing required).

          -  Any major congenital defects, serious chronic illness or organ transplantation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jojutla / Morelos</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Finland</country>
    <country>Mexico</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>September 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescent females</keyword>
  <keyword>Cytomegalovirus (CMV)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
